Pembrolizumab Nears European Approval for HNSCC

July 30, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of pembrolizumab for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who progressed following platinum-based chemotherapy and have a PD-L1 tumor proportion score (TPS) ≥50%.The CHMP recommendation is based on data from the phase III KEYNOTE-040 … (leggi tutto)